Sail's In-Body Cell Therapy Aims to Revolutionize Autoimmune Cures

CAMBRIDGE, MA – April 27, 2026 – A new frontier in medicine is emerging from the labs of Cambridge, one that seeks to transform a patient's own cells into living drugs directly within their body. Sail Biomedicines, a company backed by the prominent venture-creation firm Flagship Pioneering, is at the forefront of this movement. The company has announced it will present highly anticipated preclinical data for a revolutionary therapy designed to offer a potential cure for debilitating autoimmune diseases.

At the upcoming American Society of Gene & Cell Therapy (ASGCT) and TIDES USA conferences in May, Sail will pull back the curtain on its vanguard program: an in vivo CAR-T therapy. Unlike conventional CAR-T treatments, which require a complex and costly process of removing, engineering, and re-infusing a patient's immune cells, Sail’s approach aims to perform this entire feat inside the body using a single intravenous infusion. This breakthrough could fundamentally disrupt how millions of patients suffering from conditions like lupus, rheumatoid arthritis, and multiple sclerosis are treated.

A Paradigm Shift for Chronic Disease

For decades, patients with autoimmune diseases have been caught in a cycle of symptom management. Treatments typically involve lifelong administration of drugs that broadly suppress the immune system, leaving patients vulnerable to infections and other serious side effects. While newer biologic drugs offer more targeted action, they still require chronic use and often fail to induce a lasting remission. The concept of a cure has remained largely out of reach.

Sail Biomedicines aims to change this narrative. The company's therapy is designed to achieve what its leadership calls a "full immune reset." By programming a patient's T cells to hunt down and eliminate the rogue B-cells that drive many autoimmune conditions, the treatment could potentially eradicate the source of the disease, allowing the immune system to rebuild itself in a healthy, balanced state.

“The power of In Vivo CAR-T for curative treatments in autoimmune diseases could completely disrupt treatment paradigms for patients by achieving deep B-cell depletion in the right places for the right amount of time to achieve a full immune reset,” said John Mendlein, Ph.D., Executive Chairman of Sail Biomedicines and an Executive Partner at Flagship Pioneering, in a recent statement.

The promise is profound: replacing a lifetime of infusions and pills with a single, potentially curative treatment. For the millions living with the daily burden of autoimmune disease, such an advancement would be nothing short of transformative, offering hope for a life free from chronic illness.

The Science Behind the Sail: eRNA and Targeted Delivery

At the heart of Sail's innovative platform are two key technologies: endlessly programmable circular RNA (eRNA™) and a proprietary targeted nanoparticle (TNP) delivery system. This combination is designed to overcome many of the challenges that have historically plagued gene and cell therapy.

First is the eRNA. Unlike linear messenger RNA (mRNA), which gained fame with COVID-19 vaccines but is inherently unstable, eRNA is a closed loop. This circular structure makes it highly resistant to enzymes in the body that would normally degrade it, allowing for a more sustained and durable expression of its genetic payload. This could mean a more powerful therapeutic effect from a lower dose, a critical factor for safety and efficacy.

However, this powerful genetic code is useless without a reliable delivery vehicle. This is where the targeted nanoparticles come in. Sail has engineered these microscopic particles to act as a precision-guided missile, designed to seek out and bind specifically to CD4 and CD8 T cells—the key soldiers of the immune system. Once bound, the nanoparticle delivers its eRNA cargo, effectively turning the T cell into a CAR-T cell in situ. This non-viral approach avoids the risks associated with using viruses to deliver genetic material, such as potential immunogenicity or insertional mutagenesis.

This two-part system—a durable genetic message and a highly specific delivery truck—is what Sail believes will give its therapy a superior profile, enabling potent T-cell engagement and deep B-cell depletion with an optimal safety window.

Navigating a Competitive Sea: The In Vivo Therapy Race

Sail Biomedicines is not alone in its quest to conquer in vivo cell programming. The field is a hotbed of innovation, with several well-funded biotech companies racing to bring a new generation of genetic medicines to the clinic. Competitors like Capstan Therapeutics and Umoja Biopharma are also developing their own in vivo CAR-T platforms, each with unique technological approaches to delivering genetic instructions directly to cells inside the body. Meanwhile, gene editing pioneers like Intellia Therapeutics have already demonstrated the power of in vivo delivery with their successful CRISPR-based therapies for other diseases.

This intense competition, far from being a deterrent, serves as a powerful validation of the entire field. The collective pursuit underscores a broad consensus in the scientific and investment communities that in vivo programming is the future of cell and gene therapy. The primary challenges for all players remain the same: ensuring the delivery system is highly specific to avoid off-target effects, controlling the level and duration of CAR expression to prevent toxicity, and proving long-term safety and durability in human patients.

The data presented by Sail at the upcoming conferences will be scrutinized by the industry for clues as to how its eRNA and TNP platform measures up against these challenges and where it stands in this high-stakes race.

The Flagship Effect: Pioneering a New Class of Medicines

The ambitious vision of Sail Biomedicines is backed by one of the most successful and influential players in biotechnology: Flagship Pioneering. Known for its unique venture creation model, Flagship doesn't just invest in startups; it conceives and builds them from the ground up around breakthrough scientific ideas. Its most famous creation, Moderna, leveraged a novel mRNA platform to change the world during a global pandemic.

Flagship's involvement provides Sail with more than just capital. It offers a seal of approval, a deep well of scientific and strategic expertise, and a track record of turning audacious scientific concepts into reality. This backing lends significant credibility to Sail's platform and signals a high degree of confidence in its potential to create a new class of programmable RNA medicines.

As Sail prepares to share its preclinical findings, the entire biotech industry will be watching. The data will provide the first public glimpse into the potential of its eRNA-based in vivo CAR-T therapy and could mark a pivotal moment in the long and arduous journey toward finding a true cure for autoimmune diseases.